CA2345230A1 - Methods to selectively inactivate viruses in biological compositions - Google Patents

Methods to selectively inactivate viruses in biological compositions Download PDF

Info

Publication number
CA2345230A1
CA2345230A1 CA002345230A CA2345230A CA2345230A1 CA 2345230 A1 CA2345230 A1 CA 2345230A1 CA 002345230 A CA002345230 A CA 002345230A CA 2345230 A CA2345230 A CA 2345230A CA 2345230 A1 CA2345230 A1 CA 2345230A1
Authority
CA
Canada
Prior art keywords
preparation
composition
ethyleneimine oligomer
solution
washing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002345230A
Other languages
English (en)
French (fr)
Inventor
Clark Mcwhorter Edson
Andrei A. Purmal
Samuel K. Ackerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VI Technologies Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2345230A1 publication Critical patent/CA2345230A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2796/00—Viruses not covered by groups C12N2710/00 - C12N2795/00
CA002345230A 1998-09-25 1999-09-22 Methods to selectively inactivate viruses in biological compositions Abandoned CA2345230A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16103098A 1998-09-25 1998-09-25
US09/161,030 1998-09-25
PCT/US1999/021245 WO2000018969A1 (en) 1998-09-25 1999-09-22 Methods to selectively inactivate viruses in biological compositions

Publications (1)

Publication Number Publication Date
CA2345230A1 true CA2345230A1 (en) 2000-04-06

Family

ID=22579508

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002345230A Abandoned CA2345230A1 (en) 1998-09-25 1999-09-22 Methods to selectively inactivate viruses in biological compositions

Country Status (5)

Country Link
EP (1) EP1115889A4 (de)
JP (1) JP2002525131A (de)
AU (1) AU6497099A (de)
CA (1) CA2345230A1 (de)
WO (1) WO2000018969A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
US20050074743A1 (en) * 2003-10-06 2005-04-07 Purmal Andrei A. Method and composition for treating a biological sample
DE102005021363A1 (de) * 2005-05-04 2006-11-16 Basf Ag Biozide Beschichtungen
CN101012455B (zh) * 2005-11-14 2011-05-18 大连珍奥药业有限公司 一种生化物质的灭活方法、一种心肌肽素的制备方法及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114108A (en) * 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids

Also Published As

Publication number Publication date
AU6497099A (en) 2000-04-17
WO2000018969A1 (en) 2000-04-06
EP1115889A1 (de) 2001-07-18
EP1115889A4 (de) 2003-02-05
JP2002525131A (ja) 2002-08-13

Similar Documents

Publication Publication Date Title
Salunkhe et al. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands
Mohr et al. BLOOD COMPONENTS: A novel approach to pathogen reduction in platelet concentrates using short‐wave ultraviolet light
Seltsam et al. UVC irradiation for pathogen reduction of platelet concentrates and plasma
EP1838355B1 (de) Verbesserte quench-verfahren für ein erythrozyten-inaktivierungsverfahren
Klein Pathogen inactivation technology: cleansing the blood supply
Kleinman et al. Risks associated with red blood cell transfusions: potential benefits from application of pathogen inactivation
JP4968974B2 (ja) 血液製剤からソラレンを除去するための方法およびデバイス
JP4643004B2 (ja) 生体材料中の病原体不活性化剤をクエンチするための方法
Goodrich et al. Defining “adequate” pathogen reduction performance for transfused blood components
Li et al. Prevalence of antibody to malignant catarrhal fever virus in wild and domestic ruminants by competitive-inhibition ELISA
WO2007006012A2 (en) Methods for reducing pathogens in biological samples
US20230263833A1 (en) Compositions and methods for preparation of red blood cells
Terpstra et al. Potential and limitation of UVC irradiation for the inactivation of pathogens in platelet concentrates
Corash Inactivation of viruses, bacteria, protozoa, and leukocytes in platelet concentrates: current research perspectives
Luban Transfusion safety: Where are we today?
KR20140093603A (ko) 병원체 불활성화제로서의 글리콜
CA2345230A1 (en) Methods to selectively inactivate viruses in biological compositions
Dodd Current safety of the blood supply in the United States
Trimble et al. Assessing emerging infectious threats to blood safety for the blood disorders community
Buerger et al. Infectious Complications of Blood Transfusion
AuBuchon Update on the status of pathogen inactivation methods
US20020034724A1 (en) Methods to selectively inactivate microorganisms in biological compositions
Rios et al. Viability of red cells prepared with S‐303 pathogen inactivation treatment
Rosskopf et al. Pathogen reduction of double‐dose platelet concentrates from pools of eight buffy coats: product quality, safety, and economic aspects
Seghatchian et al. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued